Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen

🏥 Biogen has received FDA breakthrough-therapy designation for salanersen, a proposed treatment for spinal muscular atrophy (SMA).

📊 The designation is based on Phase 1b study results showing unexpected improvements in children previously treated with gene therapy.

🦴 Patients in the study regained critical functions such as sitting and walking after receiving salanersen.

⚡ The FDA breakthrough status aims to expedite development and review for drugs offering substantial improvement over existing therapies.

🧬 SMA is a rare genetic disease causing loss of motor neurons, leading to severe muscle atrophy and weakness.

💉 Salanersen is designed for once-yearly dosing, unlike Spinraza which requires dosing three times a year.

💰 Spinraza generated nearly $1.55 billion in worldwide sales last year, making salanersen a potential successor.

🤝 Biogen licensed the global rights to develop and commercialize salanersen from Ionis Pharmaceuticals.

🔬 Biogen is currently advancing a trio of Phase 3 studies for salanersen.

📅 The news was reported on June 4, 2026, by Dow Jones & Company, Inc.

Bullish Signals
  • Biogen has secured FDA breakthrough-therapy designation for salanersen, a potential successor to its blockbuster SMA drug Spinraza.
  • Phase 1b study results showed unexpected improvements on exploratory endpoints in children previously dosed with gene therapy who regained critical functions like sitting and walking after receiving salanersen.
  • Salanersen is designed for once-yearly dosing, offering a potential improvement over Spinraza which requires dosing three times a year.
  • Spinraza generated worldwide sales of nearly $1.55 billion last year, establishing a strong revenue base that salanersen aims to succeed.
  • Biogen is advancing a trio of Phase 3 studies for salanersen, indicating significant investment and commitment to the drug's development.
Risk Factors
  • The article contains no explicit negative points, risks, or concerning elements regarding Biogen (BIIB) based on the provided text.
  • All mentioned developments—FDA breakthrough designation, positive Phase 1b study results, and upcoming Phase 3 studies—are presented as positive catalysts without any stated downside implications.
Full Analysis
Biogen has secured FDA breakthrough therapy designation for salanersen, an investigational drug intended to treat spinal muscular atrophy (SMA). This designation is based on positive results from a Phase 1b study involving children who had previously received gene therapy and subsequently gained critical motor functions such as sitting and walking after receiving salanersen. The FDA's breakthrough status is designed to expedite the development and review process for drugs addressing serious conditions where preliminary data suggests substantial improvement over existing treatments. Salanersen represents a potential successor to Biogen's current blockbuster SMA drug, Spinraza, which generated approximately $1.55 billion in worldwide sales last year. Unlike Spinraza, which requires dosing three times annually, salanersen is designed for once-yearly administration. Biogen holds global rights to develop, manufacture, and commercialize the therapy through a licensing agreement with Ionis Pharmaceuticals, the drug's discoverer. The company is currently advancing a trio of Phase 3 studies for salanersen to further evaluate its efficacy and safety profile.